3 ASX Penny Stocks With Market Caps Over A$20M To Watch

In This Article:

The Australian sharemarket is poised for a slight retreat, with ASX 200 futures indicating a 0.28% drop following mixed signals from global markets and geopolitical tensions. Amidst these fluctuations, investors often seek opportunities in diverse areas such as penny stocks—an investment category that, despite its historical connotations, remains relevant today. These stocks typically represent smaller or newer companies and can offer compelling growth potential when backed by solid financials.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.795

A$145.87M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.59

A$69.16M

★★★★★★

Helloworld Travel (ASX:HLO)

A$2.02

A$328.89M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.55

A$341.08M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.77

A$97.91M

★★★★★★

EZZ Life Science Holdings (ASX:EZZ)

A$2.37

A$109.39M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.75

A$228.01M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.63

A$798.83M

★★★★★☆

Vita Life Sciences (ASX:VLS)

A$2.03

A$114.16M

★★★★★★

Servcorp (ASX:SRV)

A$4.96

A$489.38M

★★★★☆☆

Click here to see the full list of 1,044 stocks from our ASX Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Invion

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Invion Limited is a clinical-stage life-sciences company in Australia that focuses on researching and developing Photosoft technology for treating cancers, atherosclerosis, and infectious diseases, with a market cap of A$24.74 million.

Operations: The company generates revenue of A$3.69 million from its Clinical-Stage Life Sciences segment.

Market Cap: A$24.74M

Invion Limited, a clinical-stage life-sciences company focused on Photosoft technology for cancer and disease treatment, operates with a market cap of A$24.74 million and minimal revenue of A$4 million, indicating it is pre-revenue. The company has no long-term liabilities or debt but faces high share price volatility and shareholder dilution. With less than a year of cash runway, financial sustainability is uncertain without additional funding or revenue growth. Recent board changes include the appointment of Ms. Melanie Leydin as Company Secretary amid ongoing strategic decisions like the proposed 100:1 stock split to enhance capital structure flexibility.

ASX:IVX Financial Position Analysis as at Dec 2024
ASX:IVX Financial Position Analysis as at Dec 2024

Latin Resources

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Latin Resources Limited is a mining company focused on exploring and developing projects in Australia, Peru, Argentina, and Brazil with a market capitalization of A$476.24 million.